The EPS beat reflects cost management or lower-than-expected losses, but with near-zero revenue, fundamentals remain pre-commercial. The ASCO abstract acceptance is a credibility milestone that may boost investor sentiment ahead of clinical trial updates. Monitor enrollment progress in the U.S. IMPACT trial and any future revenue inflection as key catalysts.
DRTS drugs
DRTS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $7.91entry
- T+1 · 7mo ago −7.71%α −7.23% · $7.30
- T+5 · 7mo ago −4.80%α −5.20% · $7.53
- T+20 · 6mo ago +31.10%α +26.14% · $10.37
- T+60 · 4mo ago +64.48%α +59.70% · $13.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau Medical announced abstract acceptance of pooled clinical data from 58 pancreatic cancer patients at the 2026 ASCO Annual Meeting, a prestigious oncology conference. The company also reported Q4 2025 earnings with an EPS of $-0.08, beating consensus by 35.3%, though revenue was minimal at $66K. The ASCO recognition signals growing scientific validation for its Alpha DaRT therapy.
Key Financial Metrics
Key Facts
- Q4 2025 EPS: $-0.08 (consensus: $-0.12), representing a 35.3% beat
- Revenue: $66K (in line with estimates)
- Abstract on Alpha DaRT for pancreatic cancer accepted at ASCO 2026 Annual Meeting
- Data pooled from 58 patients across three clinical studies in Canada and Israel
- ASCO is the world's largest and most prestigious oncology conference
- Forward-looking commentary on U.S. IMPACT and French ACAPELLA trials ongoing
Financial Impact
EPS loss narrowed by $0.04 YoY (from $-0.14 to $-0.08), revenue remains negligible at $66K
Risk Factors
- Company remains pre-revenue with significant ongoing losses
- Clinical data is preliminary and may not predict final trial outcomes
- Heavy reliance on successful regulatory approval and future funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281701 |
Track record
25 reports on DRTS
9 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers